Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wilko Weichert

Showing results (431-440 of 504) with videos related to

Pageof 51
Sort By:
Gastroenterology|October 2, 2020
Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer BiologyKarin Feldmann, Carlo Maurer, Katja Peschke, et al.
Genes, Chromosomes & Cancer|April 23, 2020
NTRK testing: First results of the QuiP-EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA-based NGS assaysMartina Kirchner, Julia Glade, Ulrich Lehmann, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumabMarkus Eckstein, Philipp Erben, Maximilian C Kriegmair, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2018
PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO studyArndt Vogel, Stefan Kasper, Michael Bitzer, et al.
Oncotarget|September 10, 2016
Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapySilvia Darb-Esfahani, Carsten Denkert, Albrecht Stenzinger, et al.
The EMBO Journal|November 18, 2024
Towards routine proteome profiling of FFPE tissue: insights from a 1,220-case pan-cancer studyJohanna Tüshaus, Stephan Eckert, Marius Schliemann, et al.
Histopathology|August 30, 2017
Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancerAndreas H Scheel, Gudrun Baenfer, Gustavo Baretton, et al.
Medicine|January 15, 2016
Loss of BAP1 Expression Occurs Frequently in Intrahepatic CholangiocarcinomaJuliana Andrici, Benjamin Goeppert, Loretta Sioson, et al.
Oncogene|September 28, 2019
Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domainsFlorian Weinberg, Ricarda Griffin, Martina Fröhlich, et al.
British Journal of Cancer|July 21, 2022
pT3 colorectal cancer revisited: a multicentric study on the histological depth of invasion in more than 1000 pT3 carcinomas-proposal for a new pT3a/pT3b subclassificationSebastian Foersch, Corinna Lang-Schwarz, Markus Eckstein, et al.
Pageof 51

Showing results (431-440 of 504) with videos related to

Sort By:
Pageof 51
Gastroenterology|October 2, 2020
Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer BiologyKarin Feldmann, Carlo Maurer, Katja Peschke, et al.
Genes, Chromosomes & Cancer|April 23, 2020
NTRK testing: First results of the QuiP-EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA-based NGS assaysMartina Kirchner, Julia Glade, Ulrich Lehmann, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumabMarkus Eckstein, Philipp Erben, Maximilian C Kriegmair, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2018
PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO studyArndt Vogel, Stefan Kasper, Michael Bitzer, et al.
Oncotarget|September 10, 2016
Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapySilvia Darb-Esfahani, Carsten Denkert, Albrecht Stenzinger, et al.
The EMBO Journal|November 18, 2024
Towards routine proteome profiling of FFPE tissue: insights from a 1,220-case pan-cancer studyJohanna Tüshaus, Stephan Eckert, Marius Schliemann, et al.
Histopathology|August 30, 2017
Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancerAndreas H Scheel, Gudrun Baenfer, Gustavo Baretton, et al.
Medicine|January 15, 2016
Loss of BAP1 Expression Occurs Frequently in Intrahepatic CholangiocarcinomaJuliana Andrici, Benjamin Goeppert, Loretta Sioson, et al.
Oncogene|September 28, 2019
Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domainsFlorian Weinberg, Ricarda Griffin, Martina Fröhlich, et al.
British Journal of Cancer|July 21, 2022
pT3 colorectal cancer revisited: a multicentric study on the histological depth of invasion in more than 1000 pT3 carcinomas-proposal for a new pT3a/pT3b subclassificationSebastian Foersch, Corinna Lang-Schwarz, Markus Eckstein, et al.
Pageof 51